Incyte Corp [INCY] stock is trading at $62.33, up 2.33%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The INCY shares have gain 1.75% over the last week, with a monthly amount drifted -10.55%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Incyte Corp [NASDAQ: INCY] stock has seen the most recent analyst activity on March 18, 2025, when William Blair downgraded its rating to a Mkt Perform. Previously, Guggenheim downgraded its rating to Neutral on March 18, 2025. On December 17, 2024, UBS initiated with a Neutral rating and assigned a price target of $77 on the stock. BofA Securities upgraded its rating to a Buy and increased its price target to $90 on October 29, 2024. Wolfe Research initiated its recommendation with a Outperform and recommended $84 as its price target on October 01, 2024. Truist downgraded its rating to Hold for this stock on September 18, 2024, and downed its price target to $74. In a note dated July 02, 2024, BMO Capital Markets downgraded an Underperform rating on this stock and revised its target price from $52 to $48.
Incyte Corp [INCY] stock has fluctuated between $50.35 and $83.95 over the past year. Currently, Wall Street analysts expect the stock to reach $107.5 within the next 12 months. Incyte Corp [NASDAQ: INCY] shares were valued at $62.33 at the most recent close of the market. An investor can expect a potential return of 72.47% based on the average INCY price forecast.
Analyzing the INCY fundamentals
Incyte Corp [NASDAQ:INCY] reported sales of 4.24B for the trailing twelve months, which represents a growth of 16.32%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.01%, Pretax Profit Margin comes in at 0.07%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.01 and Total Capital is 0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 60.89 points at the first support level, and at 59.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 63.15, and for the 2nd resistance point, it is at 63.97.
Ratios To Look Out For
For context, Incyte Corp’s Current Ratio is 1.97. Also, the Quick Ratio is 1.94, while the Cash Ratio stands at 1.03. Considering the valuation of this stock, the price to sales ratio is 2.84, the price to book ratio is 3.50 and price to earnings (TTM) ratio is 229.83.
Transactions by insiders
Recent insider trading involved Flannelly Barry P, EVP & General Manager US, that happened on Mar 14 ’25 when 19807.0 shares were sold. Officer, BARRY FLANNELLY completed a deal on Mar 14 ’25 to buy 19807.0 shares. Meanwhile, EVP & General Counsel Denton Sheila A. sold 599.0 shares on Mar 04 ’25.
